[go: up one dir, main page]

MX2009007543A - Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero. - Google Patents

Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero.

Info

Publication number
MX2009007543A
MX2009007543A MX2009007543A MX2009007543A MX2009007543A MX 2009007543 A MX2009007543 A MX 2009007543A MX 2009007543 A MX2009007543 A MX 2009007543A MX 2009007543 A MX2009007543 A MX 2009007543A MX 2009007543 A MX2009007543 A MX 2009007543A
Authority
MX
Mexico
Prior art keywords
posaconazole
polymer conjugates
methods
treatment
conjugates
Prior art date
Application number
MX2009007543A
Other languages
English (en)
Inventor
Hong Zhao
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of MX2009007543A publication Critical patent/MX2009007543A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
    • C08G65/3318—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
    • C08G65/3326—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen composiciones mejoradas basadas en posaconazole y métodos de tratamiento y prevención de infecciones fúngicas, cáncer o enfermedades metastásicas; en aspectos preferidos, los conjugados de PEG-posaconazole en la que el PEG tiene un peso molecular de aproximadamente 20,000 daltons.
MX2009007543A 2007-01-16 2008-01-15 Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero. MX2009007543A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88508907P 2007-01-16 2007-01-16
PCT/US2008/051075 WO2008089185A2 (en) 2007-01-16 2008-01-15 Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof

Publications (1)

Publication Number Publication Date
MX2009007543A true MX2009007543A (es) 2009-10-07

Family

ID=39617952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007543A MX2009007543A (es) 2007-01-16 2008-01-15 Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero.

Country Status (7)

Country Link
US (2) US7625898B2 (es)
EP (1) EP2125014A2 (es)
JP (1) JP2010515762A (es)
CA (1) CA2675411A1 (es)
MX (1) MX2009007543A (es)
TW (1) TW200838561A (es)
WO (1) WO2008089185A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318331A1 (en) * 2010-06-29 2011-12-29 Kaohsiung Medical University Nanoparticles and Use Thereof
RS62583B1 (sr) 2010-06-29 2021-12-31 Merck Sharp & Dohme Formulacije intravenskog rastvora sa posakonazolom, stabilisane supstituisanim beta-ciklodekstrinom
CA2840215A1 (en) * 2011-06-22 2012-12-27 Abhijit S. BAPAT Conjugate-based antifungal and antibacterial prodrugs
WO2015137451A1 (ja) * 2014-03-13 2015-09-17 株式会社クラレ 重合体、吸着材、並びにその製造方法
CN104151304B (zh) * 2014-07-23 2016-08-17 王庚禹 一种三唑类化合物
WO2017066335A1 (en) 2015-10-12 2017-04-20 Bhagwandin Vikash J Compositions, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
CN108186571B (zh) * 2018-02-09 2020-07-14 苏州大学 可逆交联不对称囊泡在制备治疗急性白血病药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69225959T2 (de) * 1991-01-29 1998-12-10 Exxon Chemical Patents Inc., Linden, N.J. Verfahren um die bildung von popcornpolymer durch hitze zu verhindern
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
NO302804B1 (no) * 1995-09-08 1998-04-27 Norsk Hydro As Utstyr for horisontal direktekjölt stöping av lettmetaller, spesielt magnesium og magnesiumlegeringer
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
WO2000000548A1 (fr) * 1998-06-26 2000-01-06 Teijin Limited Compositions de polyesters aromatiques et procede de production d'articles moules et de bouteilles a partir de telles compositions
DE19835467A1 (de) * 1998-08-06 2000-02-17 Elenac Gmbh Feststoffreaktor mit antistatischer Beschichtung zur Durchführung von Reaktionen in der Gasphase
US6111034A (en) * 1998-12-31 2000-08-29 Union Carbide Chemicals & Plastics Technology Corporation Static control in olefin polymerization
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6756076B2 (en) * 2000-10-13 2004-06-29 Michael Brier Process for producing fabric articles having water-resistant and/or antimicrobial characteristics
JP2006526640A (ja) 2003-05-30 2006-11-24 コンビナトアールエックス インコーポレーティッド 新生物を治療するための併用治療
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts

Also Published As

Publication number Publication date
CA2675411A1 (en) 2008-07-24
JP2010515762A (ja) 2010-05-13
US20080171013A1 (en) 2008-07-17
US20100056543A1 (en) 2010-03-04
US7625898B2 (en) 2009-12-01
WO2008089185A2 (en) 2008-07-24
WO2008089185A3 (en) 2008-11-06
EP2125014A2 (en) 2009-12-02
TW200838561A (en) 2008-10-01

Similar Documents

Publication Publication Date Title
MX2009007543A (es) Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero.
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
TW200722098A (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in pharmaceutical compositions for treating cancer
WO2010091192A3 (en) Nanoscale platinum compounds and methods of use thereof
GB2430624B (en) Ion binding compositions
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MY156951A (en) Micromirs
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
TW200642684A (en) Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
WO2007140312A3 (en) Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2008098178A3 (en) Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
EP1831266A4 (en) RETICULATED AMINE POLYMERS
WO2010150098A3 (en) Use of quingolide in the treatment of endometriosis, pain and cancer
WO2009149150A3 (en) Composition comprising liposome-entrapped doxorubicin and methods of administration

Legal Events

Date Code Title Description
FA Abandonment or withdrawal